Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/06/2003US6558939 Proteases and variants thereof
05/06/2003US6558936 Human lipase proteins, nucleic acids encoding them, and uses of both of these
05/06/2003US6558932 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
05/06/2003US6558925 Stem cell inhibitor
05/06/2003US6558919 Nucleotide sequences coding polypeptide for use in the prevention and treatment of infections
05/06/2003US6558918 Nucleic acid that encode a cell growth regulatory protein
05/06/2003US6558914 Human lysophosphatidic acid acyltransferase
05/06/2003US6558912 Screening for modulators of apoptosis; obtain cells containing apoptosis polypeptide, incubate with binding protein, expose to modulator, monitor concentration of bound protein in presence of modulator, compare to control
05/06/2003US6558905 Diagnosing osteoporosis in humans; obtain tissue sample, extract nucleotide sequences, digest, incubate with marker probe, detect presence of preferential allele, presence of allele indicate osteoporosis
05/06/2003US6558903 Kinases and uses thereof
05/06/2003US6558708 Administering agonists or antagonists of serotonin, peptide YY, calcitonin gene related peptide, adrenergic and/or opioid receptors
05/06/2003US6558703 Porous hydroxyapatite particles as carriers for drug substances
05/06/2003US6558702 Mixture of polymer and bisphosphonate compound
05/06/2003US6558675 Mutant human hepatitis B viral strain and uses thereof
05/06/2003US6558672 Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity
05/06/2003US6558666 Chromium-containing carbohydrase enzyme food supplement composition
05/06/2003US6558661 Inhibiting binding of interferon-gamma to its native receptor
05/06/2003US6558660 Administering an amount of interleukin-9 sufficient to induce said production
05/06/2003US6558656 Oral and topical compositions and methods related thereto in the treatment of acne
05/06/2003CA2300663C Method for treating dysphagia
05/06/2003CA2153165C Recombinant anti-hiv antibody and process for preparing the same
05/06/2003CA2126691C Gapped 2' modified oligonucleotides
05/06/2003CA2121674C Biocompatible implant for the timing of ovulation in mares
05/06/2003CA2115060C Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
05/06/2003CA2109208C Radiolabeled metal-binding protein for the treatment of arthritis
05/06/2003CA2106955C Product and method for improving keratinocyte adhesion to the dermis
05/06/2003CA2101340C Combination of igf-1 and igfbp for anabolism
05/06/2003CA2082160C Humanised and chimeric monoclonal antibodies
05/06/2003CA2032864C Peptide compounds, a process for preparation thereof and pharmaceutical composition comprising the same
05/06/2003CA2031811C Toxoplasma gondii antigens, the preparation thereof and the use thereof
05/02/2003EP1306371A1 Cyclic imines
05/02/2003EP1306095A2 Methods and compositions for targeting the vasculature of solid tumors
05/02/2003EP1306092A2 Use of GLP-1 and analogs administered peripherally, in regulation of obesity
05/02/2003EP1306091A2 Stimulation of beta cell proliferation
05/02/2003EP1305635A2 Methods to identify compounds that modulate rage
05/02/2003EP1305435A1 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
05/02/2003EP1305434A2 A human disintegrin protein
05/02/2003EP1305427A1 19053, an atpase-like molecule and uses thereof
05/02/2003EP1305426A2 25324, 50287, 28899, 47007 and 42967, transferase family members, and uses therefor
05/02/2003EP1305425A2 Drug metabolizing enzymes
05/02/2003EP1305424A2 32252, a human amp-binding family member and uses thereof
05/02/2003EP1305419A2 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
05/02/2003EP1305418A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
05/02/2003EP1305417A2 Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof
05/02/2003EP1305414A2 Modified cea and uses thereof
05/02/2003EP1305409A2 Renal regulatory elements and methods of use thereof
05/02/2003EP1305406A2 Modulation of gamma-secretase activity
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305399A1 Bacillus subtilis var. chungkookjang producing high molecular weight poly-gamma-glutamic acid
05/02/2003EP1305343A2 Peptides presented by cells
05/02/2003EP1305342A2 Human kininogen d5 domain polypeptides and their use
05/02/2003EP1305340A2 Sequences for integrin alpha-8
05/02/2003EP1305338A2 Modified peptides with increased potency
05/02/2003EP1305337A2 Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
05/02/2003EP1305336A2 Therapeutic anti-melanoma compounds
05/02/2003EP1305335A2 Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders
05/02/2003EP1305334A1 Urocortin proteins and uses thereof
05/02/2003EP1305332A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305051A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
05/02/2003EP1305047A2 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
05/02/2003EP1305045A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
05/02/2003EP1305044A2 Qs-21 and il-12 as an adjuvant combination
05/02/2003EP1305013A1 Preparation with vascular protective and anti-oxidative effect and use thereof
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1213972B1 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars"
05/02/2003EP1189611A4 Cancer therapy
05/02/2003EP1128730B1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
05/02/2003EP1089712B1 Large porous particles emitted from an inhaler
05/02/2003EP1075488B1 Protein purification by ion exchange chromatography
05/02/2003EP1071456B1 Vaccines with an ltb adjuvant
05/02/2003EP1056704B1 Antitumor agents
05/02/2003EP1036167B1 Nuclear targeting by means of streptococcal protein h
05/02/2003EP1028748B1 Compositions providing for increased igf-i solubility
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP1007675A4 Porcine mhc class i genes and uses thereof
05/02/2003EP0986396A4 Prion protein modulator factor (ppmf) and prion resistant animals
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0879294B1 Transduced human hematopoietic stem cells
05/02/2003EP0876146B1 Nucleoside analogs in combination therapy of herpes simplex infections
05/02/2003EP0834321B1 Oral remedy for rheumatoid arthritis and functional food
05/02/2003EP0815130B1 Casein phosphopeptide, casein containing same and process for the preparation thereof
05/02/2003EP0802983B1 Expression of urokinase plasminogen activator inhibitors
05/02/2003EP0769964B1 Cck antibodies used to improve feed efficiency
05/02/2003EP0724459B1 Formulations for delivery of osteogenic proteins
05/02/2003EP0714435B1 Pro-urokinase mutants
05/02/2003EP0674710B1 Peptides with broad neoplastic specificity
05/01/2003WO2003036264A2 Treating diseases mediated by metalloprotease-shed proteins
05/01/2003WO2003035884A2 Transient immortalization
05/01/2003WO2003035876A1 Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus
05/01/2003WO2003035873A1 Novel glutamic acid receptor and utilization thereof
05/01/2003WO2003035872A1 Human and mammalian stem cell-derived neuronal survival polypeptides
05/01/2003WO2003035870A1 Drug for treating a carcinoma of the pancreas
05/01/2003WO2003035869A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
05/01/2003WO2003035868A1 Medicament that increases the effectiveness of a drug that induces receptor-mediated apoptosis in tumor cells
05/01/2003WO2003035862A2 Regulation of human arginase signature-containing protein
05/01/2003WO2003035861A2 Thrombin-cleavable chimeric proteins
05/01/2003WO2003035855A1 Differentiation of whole bone marrow
05/01/2003WO2003035847A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
1 ... 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 ... 3163